Stay updated on AZD8233 Safety in Elevated LDL-C Levels Clinical Trial
Sign up to get notified when there's something new on the AZD8233 Safety in Elevated LDL-C Levels Clinical Trial page.

Latest updates to the AZD8233 Safety in Elevated LDL-C Levels Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe ClinicalTrials.gov page now displays the record for AstraZeneca’s Phase 1 AZD8233 trial, including study design, eligibility, outcome measures, and information about sharing participant data.SummaryDifference78%

- Check20 days agoChange DetectedThe footer revision number changed from v3.7.2 to v3.8.0; the displayed page remains a 403 Forbidden error.SummaryDifference0.2%

- Check27 days agoChange DetectedA notice appears above the page announcing NIH website transition updates and stating that NIH content may use “Super Intelligence” in place of “Artificial Intelligence.”SummaryDifference1%

- Check34 days agoChange DetectedThe ClinicalTrials.gov page remains a 403 Forbidden error page, with the displayed site revision changing from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check41 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.0 to v3.7.1, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check62 days agoChange DetectedThe study record page now renders a 403 Forbidden error screen with the site header/footer, replacing the expected content for the NCT03593785 record.SummaryDifference24%

Stay in the know with updates to AZD8233 Safety in Elevated LDL-C Levels Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AZD8233 Safety in Elevated LDL-C Levels Clinical Trial page.